164 related articles for article (PubMed ID: 10355966)
1. Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506.
Yang J; Shikata N; Yasuda T; Matsuzawa A; Tsubura A
Pathol Int; 1999 Feb; 49(2):133-40. PubMed ID: 10355966
[TBL] [Abstract][Full Text] [Related]
2. Lacrimal and salivary gland inflammation in the C3H/Ipr autoimmune strain mouse: a potential mode for Sjögren's syndrome.
Johnson BC; Morton JI; Trune DR
Otolaryngol Head Neck Surg; 1992 Apr; 106(4):394-9. PubMed ID: 1565490
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice.
Jabs DA; Lee B; Burek CL; Saboori AM; Prendergast RA
Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):377-83. PubMed ID: 8603842
[TBL] [Abstract][Full Text] [Related]
4. Submandibular and lacrimal gland immunoglobulin in the C3H.MRL-Faslpr autoimmune mouse model of Sjögren's syndrome.
Trune DR; Leedy DA
Laryngoscope; 1998 Nov; 108(11 Pt 1):1729-32. PubMed ID: 9818834
[TBL] [Abstract][Full Text] [Related]
5. Two different types of sialoadenitis in the NOD- and MRL/lpr mouse models for Sjögren's syndrome: a differential role for dendritic cells in the initiation of sialoadenitis?
van Blokland SC; van Helden-Meeuwsen CG; Wierenga-Wolf AF; Drexhage HA; Hooijkaas H; van de Merwe JP; Versnel MA
Lab Invest; 2000 Apr; 80(4):575-85. PubMed ID: 10780673
[TBL] [Abstract][Full Text] [Related]
6. Sjögren's syndrome-like autoimmune sialadenitis in MRL-Faslpr mice is associated with expression of glucocorticoid-induced TNF receptor-related protein (GITR) ligand and 4-1BB ligand.
Saito K; Mori S; Date F; Ono M
Autoimmunity; 2013 Jun; 46(4):231-7. PubMed ID: 23301790
[TBL] [Abstract][Full Text] [Related]
7. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren's syndrome.
Sato EH; Sullivan DA
Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2632-42. PubMed ID: 8163351
[TBL] [Abstract][Full Text] [Related]
8. Impact of gender on exocrine gland inflammation in mouse models of Sjögren's syndrome.
Toda I; Sullivan BD; Rocha EM; Da Silveira LA; Wickham LA; Sullivan DA
Exp Eye Res; 1999 Oct; 69(4):355-66. PubMed ID: 10504269
[TBL] [Abstract][Full Text] [Related]
9. A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice.
Haneji N; Hamano H; Yanagi K; Hayashi Y
J Immunol; 1994 Sep; 153(6):2769-77. PubMed ID: 8077681
[TBL] [Abstract][Full Text] [Related]
10. Sjögren's syndrome in MRL/l and MRL/n mice.
Hoffman RW; Alspaugh MA; Waggie KS; Durham JB; Walker SE
Arthritis Rheum; 1984 Feb; 27(2):157-65. PubMed ID: 6421291
[TBL] [Abstract][Full Text] [Related]
11. Androgen stimulation of lacrimal gland function in mouse models of Sjögren's syndrome.
Sullivan DA; Edwards JA
J Steroid Biochem Mol Biol; 1997 Feb; 60(3-4):237-45. PubMed ID: 9191982
[TBL] [Abstract][Full Text] [Related]
12. The treatment of Sjögren's disease in NZB/NZW F1 hybrid mice with azathioprine: a two-stage study.
Yeoman CM; Franklin CD
Clin Exp Rheumatol; 1994; 12(1):49-53. PubMed ID: 8162642
[TBL] [Abstract][Full Text] [Related]
13. Murine models of Sjögren's syndrome. Evolution of the lacrimal gland inflammatory lesions.
Jabs DA; Enger C; Prendergast RA
Invest Ophthalmol Vis Sci; 1991 Feb; 32(2):371-80. PubMed ID: 1993589
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytic infiltration and goblet cell marker alteration in the conjunctiva of the MRL/MpJ-Fas(lpr) mouse model of Sjögren's syndrome.
Diebold Y; Chen LL; Tepavcevic V; Ferdman D; Hodges RR; Dartt DA
Exp Eye Res; 2007 Mar; 84(3):500-12. PubMed ID: 17208228
[TBL] [Abstract][Full Text] [Related]
15. Influence of androgen therapy on lacrimal autoimmune disease in a mouse model of Sjögren's syndrome.
Sullivan DA; Rocha FJ; Sato EH
Adv Exp Med Biol; 1995; 371B():1199-202. PubMed ID: 7502783
[No Abstract] [Full Text] [Related]
16. Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice.
Toda I; Wickham LA; Sullivan DA
Clin Immunol Immunopathol; 1998 Jan; 86(1):59-71. PubMed ID: 9434797
[TBL] [Abstract][Full Text] [Related]
17. Impact of androgen therapy in Sjögren's syndrome: hormonal influence on lymphocyte populations and Ia expression in lacrimal glands of MRL/Mp-lpr/lpr mice.
Sato EH; Ariga H; Sullivan DA
Invest Ophthalmol Vis Sci; 1992 Jul; 33(8):2537-45. PubMed ID: 1634351
[TBL] [Abstract][Full Text] [Related]
18. Ca2+ signaling by cholinergic and alpha1-adrenergic agonists is up-regulated in lacrimal and submandibular glands in a murine model of Sjögren's syndrome.
Zoukhri D; Hodges RR; Rawe IM; Dartt DA
Clin Immunol Immunopathol; 1998 Nov; 89(2):134-40. PubMed ID: 9787115
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Sjögren's syndrome-like autoimmune lesions in MRL/lpr mice.
Hayashi Y; Haneji N; Hamano H
Pathol Int; 1994 Aug; 44(8):559-68. PubMed ID: 7952145
[TBL] [Abstract][Full Text] [Related]
20. Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model.
Tsubota K; Saito I; Ishimaru N; Hayashi Y
Invest Ophthalmol Vis Sci; 1998 Aug; 39(9):1551-9. PubMed ID: 9699544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]